These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 27712045)

  • 41. Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations.
    Cao S; Tan C; Fei A; Hu G; Fu M; Lv J
    J Mol Model; 2022 Dec; 29(1):24. PubMed ID: 36576611
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RET kinase inhibitors: a review of recent patents (2012-2015).
    Mologni L; Gambacorti-Passerini C; Goekjian P; Scapozza L
    Expert Opin Ther Pat; 2017 Jan; 27(1):91-99. PubMed ID: 27646564
    [TBL] [Abstract][Full Text] [Related]  

  • 43. REToma: a cancer subtype with a shared driver oncogene.
    Kohno T; Tabata J; Nakaoku T
    Carcinogenesis; 2020 Apr; 41(2):123-129. PubMed ID: 31711124
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
    Meng X; Li Y; Tang H; Mao W; Yang H; Wang X; Ding X; Xie S
    Amino Acids; 2016 Feb; 48(2):487-97. PubMed ID: 26439378
    [TBL] [Abstract][Full Text] [Related]  

  • 45. RET inhibition: implications in cancer therapy.
    Borrello MG; Ardini E; Locati LD; Greco A; Licitra L; Pierotti MA
    Expert Opin Ther Targets; 2013 Apr; 17(4):403-19. PubMed ID: 23461584
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Central role of RET in thyroid cancer.
    Santoro M; Carlomagno F
    Cold Spring Harb Perspect Biol; 2013 Dec; 5(12):a009233. PubMed ID: 24296167
    [TBL] [Abstract][Full Text] [Related]  

  • 47. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer.
    Sala E; Mologni L; Cazzaniga S; Papinutto E; Gambacorti-Passerini C
    Int J Biol Macromol; 2006 Aug; 39(1-3):60-5. PubMed ID: 16490247
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New approaches to thyroid cancer.
    Cohen EE
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):255-6. PubMed ID: 22706487
    [No Abstract]   [Full Text] [Related]  

  • 50. Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.
    Dixit A; Torkamani A; Schork NJ; Verkhivker G
    Biophys J; 2009 Feb; 96(3):858-74. PubMed ID: 19186126
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structure and chemical inhibition of the RET tyrosine kinase domain.
    Knowles PP; Murray-Rust J; Kjaer S; Scott RP; Hanrahan S; Santoro M; Ibáñez CF; McDonald NQ
    J Biol Chem; 2006 Nov; 281(44):33577-87. PubMed ID: 16928683
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
    Henderson YC; Fredrick MJ; Clayman GL
    Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting RET alterations in cancer: Recent progress and future directions.
    Shabbir A; Kojadinovic A; Shafiq T; Mundi PS
    Crit Rev Oncol Hematol; 2023 Jan; 181():103882. PubMed ID: 36481304
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core.
    Song Z; Xia Z; Ji Y; Xing L; Gao Y; Ai J; Geng M; Zhang A
    Eur J Med Chem; 2016 Aug; 118():244-9. PubMed ID: 27131066
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.
    Sohl CD; Ryan MR; Luo B; Frey KM; Anderson KS
    ACS Chem Biol; 2015 May; 10(5):1319-29. PubMed ID: 25686244
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
    Dunna NR; Kandula V; Girdhar A; Pudutha A; Hussain T; Bandaru S; Nayarisseri A
    Asian Pac J Cancer Prev; 2015; 16(16):7089-95. PubMed ID: 26514495
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold.
    Brandt W; Mologni L; Preu L; Lemcke T; Gambacorti-Passerini C; Kunick C
    Eur J Med Chem; 2010 Jul; 45(7):2919-27. PubMed ID: 20409618
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
    Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
    Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer.
    Ni Z; Zhang TC
    J Mol Model; 2015 Jul; 21(7):175. PubMed ID: 26084268
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of RET tyrosine kinase by SU5416.
    Mologni L; Sala E; Cazzaniga S; Rostagno R; Kuoni T; Puttini M; Bain J; Cleris L; Redaelli S; Riva B; Formelli F; Scapozza L; Gambacorti-Passerini C
    J Mol Endocrinol; 2006 Oct; 37(2):199-212. PubMed ID: 17032739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.